GlaxoSmithKline Stock Rating Reaffirmed by AlphaValue (GSK)
GlaxoSmithKline (LON:GSK)‘s stock had its “sell” rating reiterated by stock analysts at AlphaValue in a report issued on Thursday, ARN reports. They currently have a GBX 1,440 ($23.07) price target on the stock. AlphaValue’s target price indicates a potential downside of 9.77% from the company’s current price.
A number of other firms have also recently commented on GSK. Analysts at Panmure Gordon reiterated a “buy” rating on shares of GlaxoSmithKline (LON:GSK) in a research note to investors on Tuesday. They now have a GBX 1,850 ($29.63) price target on the stock. Separately, analysts at Bank of America Corp. reiterated a “buy” rating on shares of GlaxoSmithKline (LON:GSK) in a research note to investors on Monday. They now have a GBX 2,050 ($32.84) price target on the stock. Finally, analysts at Bryan Garnier & Cie reiterated a “neutral” rating on shares of GlaxoSmithKline (LON:GSK) in a research note to investors on Friday, September 20th. They now have a GBX 1,900 ($30.43) price target on the stock. Five equities research analysts have rated the stock with a sell rating, nine have given a hold rating and nine have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of GBX 1,640.28 ($26.27).
GlaxoSmithKline (LON:GSK) traded up 0.37% during mid-day trading on Thursday, hitting GBX 1601.8304. 2,499,747 shares of the company’s stock traded hands. GlaxoSmithKline has a one year low of GBX 1314.00 and a one year high of GBX 1816.00. The stock has a 50-day moving average of GBX 1652. and a 200-day moving average of GBX 1640.. The company’s market cap is £77.609 billion.
GlaxoSmithKline plc (LON:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.